Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference

Rhea-AI Summary

Rigel (Nasdaq: RIGL) will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 8:30 am ET. Dean Schorno, chief financial officer, will deliver the presentation.

Investors can access a live webcast and archived recording via the Investor Relations section of Rigel's website at www.rigel.com; attendees are advised to connect to the site before the start time to allow for any software downloads.

News Market Reaction – RIGL

+2.82%

+2.82% Session close to close

In the Nov 26 session, RIGL gained 2.82%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Rigel’s participation in the Piper Sandler 37th Annual Healthcare Confe...

Analysis

This announcement highlights Rigel’s participation in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 at 8:30 am ET, extending its pattern of active engagement with investors. Recent history shows a mix of conference, earnings, and clinical updates, with some strong financial and data milestones already disclosed. Investors tracking this event may focus on any incremental color versus prior guidance, the emphasis on hematologic disorders and cancer, and how management frames upcoming clinical and commercial priorities.

Key Figures

Conference presentation time: December 3, 2025, 8:30 am ET

1 metrics

Conference presentation time December 3, 2025, 8:30 am ET Piper Sandler 37th Annual Healthcare Conference company overview

Historical Context

5 past events · Latest: Nov 26 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Nov 26	Conference appearance	Neutral	+2.8%	Announcement of Piper Sandler healthcare conference presentation webcast access.
Nov 17	Clinical data update	Positive	+1.4%	Publication of final five‑year REZLIDHIA Phase 2 data in AML.
Nov 12	Conference appearance	Neutral	+5.2%	Jefferies Global Healthcare Conference presentation with webcast access.
Nov 04	Earnings and update	Positive	-7.4%	Strong Q3 2025 financials and raised 2025 revenue guidance.
Nov 03	Conference abstracts	Positive	-2.9%	Announcement of one oral and four poster presentations at ASH.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Conference and clinical data announcements have often coincided with positive moves, while strong earnings and major data updates have occasionally seen negative reactions.

Recent Company History

This announcement fits Rigel’s pattern of active investor engagement, following multiple conference presentations and data disclosures. Recent news included strong Q3 2025 results with total revenue of $69.5M, net product sales of $64.1M, and raised full‑year revenue guidance to $285–$290M. Clinical updates highlighted five‑year REZLIDHIA data in R/R mIDH1 AML and new R289 results headed to ASH. Against this backdrop, another healthcare conference presentation extends ongoing outreach but adds limited new fundamental information.

Key Terms

hematologic disorders

1 terms

hematologic disorders medical

"a commercial stage biotechnology company focused on hematologic disorders and cancer"

Hematologic disorders are diseases that affect the blood and the organs that make blood, such as conditions causing low blood counts, abnormal clotting, or cancers of blood-forming cells. For investors, these disorders matter because they define markets for diagnostics, treatments and long-term care—think of them as problems in a city’s delivery and maintenance system: fixing them can create commercial opportunities, while persistent unmet needs can drive regulatory attention and spending.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Piper Sandler 37^th Annual Healthcare Conference on Wednesday, December 3, 2025, at 8:30 am ET.

To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

Contact for Investors & Media:
Investors: 
Rigel Pharmaceuticals, Inc. 
650.624.1232 
ir@rigel.com

Media:
David Rosen 
Argot Partners 
646.461.6387
david.rosen@argotpartners.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-present-at-the-piper-sandler-37th-annual-healthcare-conference-302626268.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

When will Rigel (RIGL) present at the Piper Sandler 2025 conference?

Rigel will present on Wednesday, December 3, 2025 at 8:30 am ET.

Who from Rigel will present at the Piper Sandler 37th Annual Healthcare Conference?

Dean Schorno, Rigel's chief financial officer, will present a company overview.

How can investors watch Rigel's (RIGL) Piper Sandler presentation live or on demand?

Access the live webcast or archived recording via the Investor Relations section at www.rigel.com.

What should viewers do before Rigel's webcast on December 3, 2025?

Viewers should connect to Rigel's website prior to the start to allow time for any required software downloads.

Does Rigel provide investor contacts for the Piper Sandler presentation?

Yes; investor inquiries can be directed to Rigel at 650.624.1232 or ir@rigel.com.